Rejected at 10:31 p.m. Feb, 20, 2024 ] by Cameron
Author: vin014
Related Note: 1509741728595
Rationale for change

Azoles are specifically indicated in inhibiting 14a-demethylase, multiple sources do not indicate its usage in the squalene to ergosterol pathway

https://next.amboss.com/us/article/6m0jgg?utm_source=navbar&utm_medium=anki&utm_campaign=anki&utm_term=azoles&guid=E%252A2umXLDGg&aid=06c2b6e6-d89f-476c-be89-0f1e8bae8bee&uid=nwcT7jepa#Z22c0acb27ee59b787c952e2e761d77fe

under azoles, it describes azoles' action against 14a-demethylase only and under the allylamines (terbinafine) there it does specify that those drugs inhibit the squalene -> ergosterol pathway

https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018827s046lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019949s065,020090s047lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208562s006lbl.pdf

various azole drugs are specified to inhibit only the lanosterol -> ergosterol pathway via inhibition of 14a-demethylase/cyp450 enzyme without mention of squalene in each one. They are from various years which demonstrates the continuity of the MOA for azoles. You can ctrl+f for MOA in each FDA link

https://usmle-rx.scholarrx.com/first-aid?id=418&firstAidYear=2023
(FA 2023 p196-1) specifies that azoles affect the lanosterol to ergosterol pathway by inhibiting cyp450 enzyme (14a-demethylase)

Rejection reason

Comments, also look at image in extra

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step1_v12::#NinjaNerd::03_Microbiology::04_Pharmacology::02_Antifungals #AK_Step1_v12::#SketchyPharm::07_Antimicrobials::05_Antifungals::03_Griseofulvin,_Terbinafine,_Echinocandins #AK_Other::#AK_Original_Decks::Step_1::Lolnotacop::Drugs #AK_Step1_v12::#Pixorize::04_Microbiology::02_Antifungals::05_Terbinafine #AK_Step1_v12::#FirstAid::03_Microbiology::07_Antimicrobials::34_Azoles #PANCE::DERM::infectious_diseases #AK_Step1_v12::#Bootcamp::Microbiology::37_Antifungals::01_General_Principles_of_Azoles #PANCE::EOR::PEDS #AK_Step1_v12::#Bootcamp::Microbiology::37_Antifungals::03_Allylamines,_Echinocandins,_and_Polyenes #AK_Step1_v12::#FirstAid::03_Microbiology::07_Antimicrobials::35_Terbinafine #AK_Step1_v12::#SketchyPharm::07_Antimicrobials::05_Antifungals::00_Overview #AK_Step1_v12::#NBME::31 #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step1_v12::#OME::PreClinical::Microbiology::Microbiology_4::Fungi::Fungi #AK_Step1_v12::#FirstAid::03_Microbiology::07_Antimicrobials::30_Antifungal_therapy #AK_Step2_v12::#B&B::08_Infectious_Disease::02_Fungi_and_Parasites::02_Antifungal_Drugs::Extra #AK_Step1_v12::#Pixorize::04_Microbiology::02_Antifungals::04_Azoles